About HLB LifeScience
HLB LifeScience is a publicly listed company based in Seongnam-si (South Korea) founded in 1998. Therapeutics for cancer treatment, including Rivoceranib and Pyrotinib, are developed. The company has 169 employees. HLB LifeScience has completed 1 acquisition, including AIM. Its chief executive, as recorded, is Yang Gon Jin. Its focus areas include Life Sciences, Oncology, Drugs and Diversified.
Company details
Founded in 1998 and based in Seongnam-si, South Korea, therapeutics for oncology are developed by HLB LifeScience in the biopharmaceutical sector. Focus is placed on treatments such as Rivoceranib for stomach and liver cancers, Pyrotinib for non-small cell lung cancer, and other anticancer agents. Operations center on research and development to address various cancer types through targeted drug innovations.
- Headquarters Seongnam-si, South Korea
- Employees 169
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website hlb-ls.com
- Legal Name Hlb Life Science Co.,Ltd.
- Annual Revenue$31.68 M (USD)39.61as on Dec 31, 2025
- Net Profit-$69.1 M (USD)-1725.88as on Dec 31, 2025
- EBITDA-$10.97 M (USD)-11.01as on Dec 31, 2025
- Employee Count169
- Investments & Acquisitions
People of HLB LifeScience
1 people are tracked at HLB LifeScience (1 in leadership); the tracked headcount is 169.
| Name | Role | Group |
|---|---|---|
Yang Gon Jin | CEO | Leadership |
Complete people profiles for HLB LifeScience
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of HLB LifeScience
HLB LifeScience is a publicly listed company on the KRX with ticker symbol 067630 in South Korea, operating in the Distribution services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date15 Oct 2010
- Listed onKRX: 067630
- Listed entityHLB Life Science Co.,Ltd.
- Exchange sectorDistribution services
- ISINKR7067630004
- Share price3,825.00 KRW (-2.42% on the day) · 2026-10-14
- Market capitalisation477,640,778,809.00 KRW
- EPS (diluted, trailing year)-271.72 KRW
- Volume (last session)411,747
Financials of HLB LifeScience
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 45.75B KRW | -99.79B KRW | -15.84B KRW |
| 2024 | 32.77B KRW | 6.14B KRW | -14.26B KRW |
| 2023 | 97.99B KRW | -5.98B KRW | -17.82B KRW |
| 2022 | 99.59B KRW | -54.28B KRW | -14.98B KRW |
| 2021 | 53.49B KRW | -49.15B KRW | -16.26B KRW |
Detailed financial statements for HLB LifeScience
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by HLB LifeScience
HLB LifeScience has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include AIM.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Automated wealth management is delivered via mobile robo-advisor app. | getaim.co | Seoul, South Korea | 2016 | May 2022 | $78.93M |
Complete acquisition details for HLB LifeScience
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of HLB LifeScience
3 dated milestones of HLB LifeScience across 24 years, from founding to its latest funding, stage changes and deals.
- Founded HLB LifeScience is founded.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires AIM.
Web traffic of HLB LifeScience
The website of HLB LifeScience (hlb-ls.com) receives about 4.1K visits a month.
- Monthly visits4.1K
▲ 7.3% vs previous month
Websites whose visitors overlap most with HLB LifeScience. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| hlbkorea.com | 100% | 15.5K | #1,449,705 | View details | |
delighti.co.kr | delighti.co.kr | 73% | #935,405 | – | |
fntimes.com | fntimes.com | 73% | #129,903 | – | |
newsdream.kr | newsdream.kr | 73% | #859,237 | – | |
pointdaily.co.kr | pointdaily.co.kr | 73% | #326,657 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 14 similar websites and full traffic analytics for HLB LifeScience
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 14 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Hlb Lifescience
Complete news archive for HLB LifeScience
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about HLB LifeScience
HLB LifeScience was founded in 1998.
HLB LifeScience is headquartered in Seongnam-si, South Korea. It is registered at Seongnam-si, Gyeonggi-do, South Korea.
Yang Gon Jin is the CEO of HLB LifeScience, as recorded in our data.
HLB LifeScience has 169 employees.
Annual revenue of HLB LifeScience is $31.68M as on Dec 31, 2025.
Founded in 1998 and based in Seongnam-si, South Korea, therapeutics for oncology are developed by HLB LifeScience in the biopharmaceutical sector. Focus is placed on treatments such as Rivoceranib for stomach and liver cancers, Pyrotinib for non-small cell lung cancer, and other anticancer agents. Operations center on research and development to address various cancer types through targeted drug innovations.
Yes, HLB LifeScience is publicly traded on KRX under the ticker symbol 067630.
HLB LifeScience has made 1 acquisition, including AIM.